(STE) STERIS - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: IE00BFY8C754

Sterilizers, Washers, Disinfectants, Sterilization Services, Surgical Tables

Health Care Equipment
Market Cap in USD: 24,627m

IPO / Inception: 1992-06-01
Return 12m vs S&P 500: 4.22%

EPS (Earnings per Share)

EPS CAGR: 4.16%
EPS Trend: 71.7%

Last SUE: 1.35
Qual. Beats: 3

Revenue

Rev. CAGR: 5.17%
Rev. Trend: 71.4%

Last SUE: 0.26
Qual. Beats: 0

Dividends

Dividend Yield	0.93%
Yield on Cost 5y	1.25%
Yield CAGR 5y	9.65%
Payout Consistency	94.1%
Payout Ratio	24.3%

Risk via 5d forecast
Volatility	21.7%
Value at Risk 5%th	33.8%
Relative Tail Risk	-5.27%

Reward TTM
Sharpe Ratio	0.86
Alpha	13.74
CAGR/Max DD	0.48

Character TTM
Hurst Exponent	0.471
Beta	0.512
Beta Downside	0.487

Drawdowns 3y
Max DD	19.93%
Mean DD	6.83%
Median DD	5.79%

Description: STE STERIS December 17, 2025

STERIS plc (NYSE: STE) supplies infection-prevention products and services worldwide through three operating segments. The Healthcare segment delivers cleaning chemistries, endoscope reprocessing systems, sterile-processing equipment, and related capital-equipment services. The Applied Sterilization Technologies (AST) segment offers contract sterilization and testing for medical-device and pharmaceutical makers, plus integrated sterilization equipment. The Life Sciences segment manufactures consumables (e.g., detergents, disinfectants, vaporized-hydrogen-peroxide systems) and high-purity water/steam generators, together with installation and maintenance services. The company serves hospitals, other health-care providers, and pharma manufacturers, and is headquartered in Mentor, Ohio.

Key recent metrics: FY 2023 revenue reached roughly $3.5 billion, up about 6 % YoY, driven by strong demand for endoscope reprocessing solutions as hospitals expand procedural volumes post-COVID-19. Operating margin stabilized near 14 % and cash-conversion remained above 80 %, supporting a growing backlog of ~ $1.2 billion. Sector-wide, the global infection-control market is projected to grow at a CAGR of 7-8 % through 2028, while capital-equipment spending in U.S. hospitals is expected to rise 4 % annually, both of which underpin STE’s growth outlook.

For a deeper, data-driven assessment of STE’s valuation and risk profile, you may find the analysis on ValueRay worth a look.

Piotroski VR‑10 (Strict, 0-10) 9.0

Net Income (688.5m TTM) > 0 and > 6% of Revenue (6% = 342.2m TTM)

FCFTA 0.09 (>2.0%) and ΔFCFTA 2.59pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 21.35% (prev 22.55%; Δ -1.20pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.13 (>3.0%) and CFO 1.30b > Net Income 688.5m (YES >=105%, WARN >=100%)

Net Debt (1.74b) to EBITDA (1.47b) ratio: 1.19 <= 3.0 (WARN <= 3.5)

Current Ratio 2.37 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (98.8m) change vs 12m ago -0.41% (target <= -2.0% for YES)

Gross Margin 44.29% (prev 43.00%; Δ 1.28pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 55.22% (prev 49.04%; Δ 6.19pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 14.60 (EBITDA TTM 1.47b / Interest Expense TTM 67.0m) >= 6 (WARN >= 3)

Altman Z'' 4.43

(A) 0.12 = (Total Current Assets 2.11b - Total Current Liabilities 888.9m) / Total Assets 10.41b

(B) 0.26 = Retained Earnings (Balance) 2.73b / Total Assets 10.41b

(D) 2.07 = Book Value of Equity 7.01b / Total Liabilities 3.39b

Total Rating: 4.43 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 75.36

1. Piotroski 9.0pt

2. FCF Yield 3.65%

3. FCF Margin 16.86%

4. Debt/Equity 0.29

5. Debt/Ebitda 1.19

6. ROIC - WACC (= 1.26)%

7. RoE 10.21%

8. Rev. Trend 71.43%

9. EPS Trend 71.65%

What is the price of STE shares?

As of January 12, 2026, the stock is trading at USD 256.82 with a total of 290,655 shares traded.
Over the past week, the price has changed by +2.71%, over one month by -0.17%, over three months by +7.53% and over the past year by +26.08%.

Is STE a buy, sell or hold?

STERIS has received a consensus analysts rating of 3.80. Therefor, it is recommend to hold STE.

Strong Buy: 3
Buy: 2
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the STE price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	281.6	9.7%
Analysts Target Price	281.6	9.7%
ValueRay Target Price	282.8	10.1%

STE Fundamental Data Overview January 04, 2026

P/E Trailing = 35.8224
P/E Forward = 22.779
P/S = 4.3186
P/B = 3.55
P/EG = 1.7388
Beta = 1.014
Revenue TTM = 5.70b USD
EBIT TTM = 978.1m USD
EBITDA TTM = 1.47b USD
Long Term Debt = 1.90b USD (from longTermDebt, last quarter)
Short Term Debt = 35.3m USD (from shortTermDebt, last quarter)
Debt = 2.06b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.74b USD (from netDebt column, last quarter)
Enterprise Value = 26.37b USD (24.63b + Debt 2.06b - CCE 319.2m)
Interest Coverage Ratio = 14.60 (Ebit TTM 978.1m / Interest Expense TTM 67.0m)
EV/FCF = 27.43x (Enterprise Value 26.37b / FCF TTM 961.2m)
FCF Yield = 3.65% (FCF TTM 961.2m / Enterprise Value 26.37b)
FCF Margin = 16.86% (FCF TTM 961.2m / Revenue TTM 5.70b)
Net Margin = 12.07% (Net Income TTM 688.5m / Revenue TTM 5.70b)
Gross Margin = 44.29% ((Revenue TTM 5.70b - Cost of Revenue TTM 3.18b) / Revenue TTM)
Gross Margin QoQ = 44.23% (prev 45.14%)
Tobins Q-Ratio = 2.53 (Enterprise Value 26.37b / Total Assets 10.41b)
Interest Expense / Debt = 0.72% (Interest Expense 14.9m / Debt 2.06b)
Taxrate = 23.94% (60.6m / 253.1m)
NOPAT = 743.9m (EBIT 978.1m * (1 - 23.94%))
Current Ratio = 2.37 (Total Current Assets 2.11b / Total Current Liabilities 888.9m)
Debt / Equity = 0.29 (Debt 2.06b / totalStockholderEquity, last quarter 7.01b)
Debt / EBITDA = 1.19 (Net Debt 1.74b / EBITDA 1.47b)
Debt / FCF = 1.81 (Net Debt 1.74b / FCF TTM 961.2m)
Total Stockholder Equity = 6.75b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.67% (Net Income 688.5m / Total Assets 10.41b)
RoE = 10.21% (Net Income TTM 688.5m / Total Stockholder Equity 6.75b)
RoCE = 11.32% (EBIT 978.1m / Capital Employed (Equity 6.75b + L.T.Debt 1.90b))
RoIC = 8.50% (NOPAT 743.9m / Invested Capital 8.75b)
WACC = 7.24% (E(24.63b)/V(26.69b) * Re(7.80%) + D(2.06b)/V(26.69b) * Rd(0.72%) * (1-Tc(0.24)))
Discount Rate = 7.80% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.28%
[DCF Debug] Terminal Value 83.77% ; FCFF base≈848.8m ; Y1≈1.05b ; Y5≈1.78b
Fair Price DCF = 344.7 (EV 35.57b - Net Debt 1.74b = Equity 33.83b / Shares 98.1m; r=7.24% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 71.65 | EPS CAGR: 4.16% | SUE: 1.35 | # QB: 3
Revenue Correlation: 71.43 | Revenue CAGR: 5.17% | SUE: 0.26 | # QB: 0
EPS current Year (2026-03-31): EPS=10.21 | Chg30d=+0.107 | Revisions Net=+6 | Growth EPS=+9.4% | Growth Revenue=+8.5%
EPS next Year (2027-03-31): EPS=11.13 | Chg30d=+0.098 | Revisions Net=+6 | Growth EPS=+9.1% | Growth Revenue=+6.2%

Additional Sources for STE Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle